Sökning: L773:1558 7673 OR L773:1938 0682
> (2013) >
Two-Year Survival F...
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
-
- Nilsson, Sten (författare)
- Karolinska Institutet,Karolinska University Hospital, Sweden
-
- Franzén, Lars (författare)
- Umeå universitet,Onkologi,Länssjukhuset Sundsvall-Härnösand County Hospital, Sundsvall, Sweden, Umeå University Hospital, Sweden
-
- Parker, Christopher (författare)
- Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
-
visa fler...
-
- Tyrrell, Christopher (författare)
- Derriford Hospital, Plymouth, UK
-
- Blom, Rene (författare)
- Östergötlands Läns Landsting
-
- Tennvall, Jan (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University, Sweden
-
- Lennernäs, Bo (författare)
- Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Petersson, Ulf (författare)
- Centrallasaretteti Västerås, Sweden
-
- Johannessen, Dag C. (författare)
- Haukeland Hospital, Bergen, Norway
-
- Sokal, Michael (författare)
- Nottingham City Hospital, UK
-
- Pigott, Katharine (författare)
- Royal Free Hospital, London, UK
-
- Gillies O'Bryan-Tear, Charles (författare)
- Algeta ASA, Oslo, Norway
-
- Thuresson, Marcus (författare)
- Statisticon, Uppsala, Sweden
-
- Bolstad, Björg (författare)
- Algeta ASA, Oslo, Norway
-
- Bruland, Öyvind S. (författare)
- University of Oslo, Norway
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2013
- 2013
- Engelska.
-
Ingår i: Clinical Genitourinary Cancer. - : Elsevier. - 1558-7673 .- 1938-0682. ; 11:1, s. 20-26
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- In this 24-month follow-up of a phase II study in patients with castration-resistant prostate cancer (CRPC) and bone metastases, radium-223 (4 injections of 50 kBq/kg every 4 weeks [n = 33]) improved median overall survival vs. matching placebo (n = 31) (65.3 vs. 46.4 weeks, respectively; log-rank P = .056), with no long-term safety concerns. Data suggest that treatment of bone disease with radium-223 has survival benefits. less thanbrgreater than less thanbrgreater thanBackground: This phase II randomized, placebo-controlled study was conducted to evaluate efficacy and safety of radium-223 in patients with castration-resistant prostate cancer (CRPC) and painful bone metastases. Twelve-and 18-month survival results were reported previously. Here we report 24-month overall survival (OS) and safety data from the period 12 to 24 months after the first injection of study medication. Methods: Patients with CRPC and bone pain were randomized 1: 1 to receive 4 injections of radium-223 (50 kBq/kg [n = 33]) or placebo (n = 31) after external-beam radiotherapy; each injection was given every 4 weeks. Endpoints for this report were 24-month OS, long-term safety, and treatment-related adverse events (AEs) occurring in the 12- to 24-month period. Results: After 24 months, 10 (30%) patients were alive in the radium-223 group compared with 4 patients (13%) in the placebo group. Patients who received at least 1 dose of study medication had a median OS of 65 weeks in the radium-223 group vs. 46 weeks in the placebo group (log-rank P = .056). The hazard ratio (HR) for OS, adjusted for baseline covariates, was 0.476 (95% confidence interval [CI], 0.258-0.877; Cox regression P = .017). The most frequent cause of death for both arms was disease progression. There were no reports of treatment-related AEs or long-term hematologic toxicity during the 12- to 24-month follow-up. Conclusion: Radium-223 had a highly favorable safety profile, with no evidence of second malignancies at 24-month follow-up. The significant improvement in OS observed in patients receiving radium-223 vs. placebo suggests that treatment of bone disease with radium-223 has survival benefits. Clinical Genitourinary Cancer, Vol. 11, No. 1, 20-6
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Alpha-pharmaceutical
- Castration-resistant prostate cancer
- Overall survival
- Targeted alpha-emitter
- Alpha-pharmaceutical
- Castration-resistant prostate cancer
- Overall
- survival
- Targeted alpha-emitter
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, Sten
-
Franzén, Lars
-
Parker, Christop ...
-
Tyrrell, Christo ...
-
Blom, Rene
-
Tennvall, Jan
-
visa fler...
-
Lennernäs, Bo
-
Petersson, Ulf
-
Johannessen, Dag ...
-
Sokal, Michael
-
Pigott, Katharin ...
-
Gillies O'Bryan- ...
-
Thuresson, Marcu ...
-
Bolstad, Björg
-
Bruland, Öyvind ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Clinical Genitou ...
- Av lärosätet
-
Linköpings universitet
-
Lunds universitet
-
Karolinska Institutet
-
Umeå universitet